Article Information
History
- February 15, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Harold E Lebovitz, MD1,
- Alexander Fleming, MD2,
- Alan D Cherrington, MD3,
- Shashank Joshi, MD4,
- Sandeep N. Athalye, MD5,
- Subramanian Loganathan, MD5,*,
- Ashwini Vishweswaramurthy, MD5,
- Jayanti Panda, M.Pharm5 and
- Ashwani Marwah, M.Sc5
- 1State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
- 2Kinexum, Harpers Ferry, West Virginia, USA
- 3Vanderbilt University School of Medicine-Basic Sciences, Nashville, Tennessee, USA
- 4Consultant, Joshi Clinic and Lilavati Hospital, Mumbai, Maharashtra, India
- 5Affiliated to Biocon Biologics Ltd., Bengaluru, Karnataka, India, at the time of preparation of this manuscript
- ↵*Corresponding author: Dr Subramanian Loganathan,
Biocon Biologics Limited, Biocon House, Semicon Park, Electronic City Phase 2, Bangalore (Karnataka), 560010, India, Email ID: subramanian.l101{at}biocon.com
Posted February 15, 2022.
Efficacy and Safety of Tregopil, a Novel, Ultra-Rapid Acting Oral Prandial Insulin Analog, as Part of a Basal-Bolus Regimen in Type 2 Diabetes: A Randomized, Active Controlled Phase 3 Study
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos